Additionally, ERBB2 may modulate the tumor microenvironment by upregulating programmed death-ligand 1 (PD-L1), potentially contributing to immune evasion, which could explain its association with aggressive disease phenotypes in familial breast cancer and specific clinical factors such as hormonal status and chronic conditions. The gene discussed is ERBB2; the disease is neoplasm.